Microbot Medical Inc.
Microbot Medical Inc. is a development-stage medical device company focused on robotic-assisted endovascular surgery. Its core effort is the LIBERTY® Endovascular Robotic Surgical System, a platform intended to help physicians perform vascular procedures with remote robotic control and improved precision.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueThe LIBERTY® platform and related robotic hardware/software for minimally invasive vascular procedures.
Engineering, prototype materials, and research studies used to advance the device pipeline.
Activities supporting clinical, regulatory, and market launch readiness for the system.
Patent portfolio work and related development-stage support costs tied to the platform.
Customers
Microbot is not yet generating revenue, so it does not have a broad commercial customer base today. Its eventual buyers are expected to be hospitals, interventional physicians, and healthcare systems that perform endovascular procedures and want robotic assistance for precision, workflow, and operator safety. The company also depends on investors and grant providers to fund development until commercialization scales.
Future purchasers of the LIBERTY system for vascular procedure rooms and interventional suites.
Clinical users who would adopt the platform to improve control, precision, and ergonomics.
Public funding sources such as the Israeli Innovation Authority that support R&D.
Capital providers that fund operations until product commercialization generates revenue.
Strategy
Microbot’s near-term strategy is to fund and complete commercialization of the LIBERTY® Endovascular Robotic Surgical System while continuing R&D on future versions and applications. The company is also prioritizing capital raising through equity-linked financings and ATM usage to support working capital, public-company costs, and development milestones.
The company needs product launch success to transition from development-stage funding to operating revenue.
Microbot currently relies on external financing to fund operations and development.
Pipeline expansion can extend the platform beyond the initial product and broaden market opportunity.
Geography
Microbot is headquartered in the United States but has meaningful operational exposure to Israel through its office, subcontractors, vendors, and regulatory support activities. The company specifically notes that military operations and flight disruptions in Israel can affect importing materials, shipping devices, and supporting clinical and regulatory milestones. No country-level revenue is disclosed because the company has not yet generated operating revenue.
Risks
Microbot remains a pre-revenue company, so its business model depends on successful product development, regulatory progress, and repeated access to capital. The company also faces operational exposure in Israel, where military disruptions can affect suppliers, logistics, and clinical/regulatory work, while future dilution and debt covenants could constrain shareholders and operations.
The company has not generated revenue and must fund commercialization through equity, debt, and option exercises.
Exposure: Ongoing operating and commercialization funding
Israeli subcontractors, vendors, flights, and import/shipping channels can be disrupted by military activity.
The company must convert a development-stage product into a marketable system with regulatory and adoption milestones.
Exposure: LIBERTY launch and future product versions
R&D, public-company, and commercialization costs continue before revenue generation begins.
Exposure: Operating cash flow and liquidity
Accounting
Judgemental itemsPrototype materials, studies, personnel, and patent costs are expensed as incurred, driving reported losses.
Impact: Affects operating loss and cash burn visibility
Israeli grant funding offsets development costs, while future royalties may be payable on LIBERTY sales.
Impact: Affects net R&D expense and future gross margin economics
The company measures certain instruments at fair value, which can introduce non-cash volatility.
Impact: Can affect earnings and balance sheet values
Recent financings and option exercises change share count and cash balances.
Impact: Affects dilution, cash resources, and per-share metrics
The company has not recorded tax benefits because future taxable income is uncertain.
Impact: Limits deferred tax asset recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Micropolis AI Robotics
MCRP · Motor Vehicle Parts & Accessories
Micropolis AI Robotics designs and manufactures autonomous mobile robots built on wheeled electric vehicle platforms.
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
MicroVision, Inc
MVIS · Electronic Components, NEC
Stryker Corporation
SYK · Surgical & Medical Instruments & Apparatus
GBT Technologies Inc.
GTCH · Services-Management Consulting Services
Merit Medical Systems, Inc
MMSI · Surgical & Medical Instruments & Apparatus
Merit Medical Systems designs, manufactures, and markets proprietary medical devices used in interventional, diagnostic, and therapeutic procedures.
Last updated: 24/09/2026